Li Yongliang, Karjalainen Antti, Koskinen Heikki, Hemminki Kari, Vainio Harri, Shnaidman Michael, Ying Zhiliang, Pukkala Eero, Brandt-Rauf Paul W
Department of Environmental Health Sciences, Columbia University, New York, NY 10032, USA.
Int J Cancer. 2005 Mar 10;114(1):157-60. doi: 10.1002/ijc.20715.
Because TP53 mutations can induce an immune response and can occur early in the carcinogenic process for some tumors, p53 autoantibodies may be useful biomarkers for risk of development of cancer. Using banked serum samples from an asbestosis cohort at high risk for cancer, we demonstrate for the first time a statistically significant relationship between p53 autoantibodies and the subsequent development of malignancy (hazard ratio [HR] = 5.5, 95% confidence interval [CI] = 2.8-10.9) with a positive predictive value of 0.76 and an average lead time to diagnosis of 3.5 years. p53 autoantibodies were also significantly associated with p53 alterations in the resultant tumors (kappa = 0.78, p = 0.01).
由于TP53突变可引发免疫反应，且在某些肿瘤的致癌过程中可早期出现，因此p53自身抗体可能是癌症发生风险的有用生物标志物。我们利用来自患癌高风险石棉沉着病队列的储存血清样本，首次证明p53自身抗体与随后发生恶性肿瘤之间存在统计学上的显著关联（风险比[HR]=5.5，95%置信区间[CI]=2.8-10.9），阳性预测值为0.76，平均诊断提前期为3.5年。p53自身抗体也与所形成肿瘤中的p53改变显著相关（kappa=0.78，p=0.01）。
